Hermetica Superfood Encyclopedia
The Short Answer
Banisteriopsis caapi contains β-carboline alkaloids—harmine (1.26–3.71%), harmaline (0.12–0.59%), and tetrahydroharmine (0.29–3.48%)—that act as potent reversible inhibitors of monoamine oxidase A (MAO-A) with harmine IC₅₀ of 2.0 nM and harmaline IC₅₀ of 2.5 nM. Preclinical in vitro evidence in BV-2 microglial cells demonstrates that harmaline and the alkaloid fraction F5 suppress pro-inflammatory cytokines IL-2, IL-6, IL-17, and TNF at concentrations ≥2.5 µM, suggesting neuroprotective potential, though no human clinical trials on the vine as a standalone agent have been completed.
CategoryHerb
GroupAmazonian
Evidence LevelPreliminary
Primary KeywordBanisteriopsis caapi benefits
Ayahuasca Vine — botanical close-up
Health Benefits
**MAO-A Inhibition and Monoamine Modulation**
Harmine and harmaline reversibly inhibit MAO-A with IC₅₀ values of 2.0 nM and 2.5 nM respectively, reducing breakdown of serotonin, dopamine, and norepinephrine; standardized extracts achieve MAO-A IC₅₀ of 0.024–0.047 µg/mL, suggesting potent monoaminergic activity relevant to mood regulation.
**Neuroinflammation Suppression**
Harmaline and the LC-MS/MS-identified fraction F5 (≥2.5 µM) significantly reduce pro-inflammatory cytokines IL-2, IL-6, IL-17, and TNF in lipopolysaccharide-stimulated BV-2 microglial cells, with F5 reducing cytokine levels to undetectable concentrations at higher doses, pointing toward a potential role in neuroinflammatory conditions.
**Antioxidant Activity**: Flavonoids epicatechin (0
6–5.4% in standardized stem extracts) and procyanidin B2 (0.9–7.2%) contribute measurable antioxidant capacity, with epicatechin demonstrating an antioxidant IC₅₀ of 0.16 µg/mL and weak MAO-A inhibition (IC₅₀ 51.7×10³ nM), providing complementary free-radical scavenging independent of the β-carboline alkaloids.
**Potential Neuroprotective Effects**
THH (tetrahydroharmine) at concentrations ≥9.3 µM suppresses pro-inflammatory cytokines in microglial cells and, as a weaker MAO-A inhibitor (IC₅₀ 74 nM) relative to harmine, may modulate serotonin availability through selective reuptake inhibition; this dual mechanism is hypothesized to contribute to neuroprotection in preclinical models.
**Ritualistic and Psychospiritual Healing**
Within traditional Amazonian medicine, the vine is used as the foundational ingredient in ayahuasca decoctions administered by trained shamans (curanderos) for psychological integration, trauma processing, and spiritual healing; modern observational studies on ayahuasca ceremonies report reduced scores on depression and anxiety scales, though isolating the vine's contribution from DMT-containing admixtures remains methodologically challenging.
**Anti-inflammatory Modulation**
Beyond neuroinflammation, the β-carboline alkaloid profile and polyphenolic content of B. caapi extracts collectively suppress multiple inflammatory cytokine pathways in microglial cells; this broad cytokine suppression profile suggests potential relevance to systemic inflammatory states, though evidence remains entirely preclinical.
**Potential Antidepressant Activity**
MAO-A inhibition by harmine and harmaline mimics the pharmacological mechanism of classical antidepressant drugs; preclinical data and translational reasoning from the ayahuasca literature suggest antidepressant-relevant pharmacodynamics, but controlled human trials specifically on isolated B. caapi extracts have not been conducted.
Origin & History
Natural habitat
Banisteriopsis caapi is a large woody liana native to the Amazon Basin, distributed across Peru, Brazil, Colombia, Ecuador, and Bolivia, where it thrives in tropical rainforest understory conditions with high humidity and rich alluvial soils. Indigenous peoples have cultivated and wildcrafted the vine for centuries, propagating it through stem cuttings near riverbanks and forest clearings. Its cultivation is deeply embedded in the cultural practices of Amazonian nations including the Shipibo-Conibo, Shuar, and numerous other indigenous groups who regard it as a sacred plant teacher.
“Banisteriopsis caapi has been used as a sacred ceremonial plant by Amazonian indigenous peoples for at least several centuries, with some ethnobotanical accounts suggesting ritual use extending over a millennium across nations including the Shipibo-Conibo of Peru, the Tukano of Colombia, and the Shuar of Ecuador. Known by names including 'yagé' in Colombia and 'caapi' in Brazil, the vine is regarded in many traditions as a sentient plant teacher or 'mareación' (intoxicant for healing) that enables shamans (curanderos or vegetalistas) to diagnose illness, communicate with spirits, and perform healing rituals for physical and psychological ailments. Preparation traditionally involves harvesting mature vine stems, pounding them to expose the cambium, and conducting prolonged boiling decoctions—often with icaros (sacred songs) sung throughout—reflecting a pharmacological and spiritual integration inseparable from its use. The first formal scientific description of the plant was published by Richard Spruce in 1851 following his Amazonian botanical expeditions, and subsequent alkaloid isolation work in the early 20th century by Fischer Cardenas and others revealed the β-carboline constituents responsible for its psychoactive properties.”Traditional Medicine
Scientific Research
The evidence base for Banisteriopsis caapi as a standalone medicinal ingredient is limited to preclinical in vitro studies; no randomized controlled trials (RCTs) or controlled human clinical trials specifically isolating B. caapi extract have been identified in the peer-reviewed literature. Available laboratory research includes cytokine assays in BV-2 murine microglial cells (n=5–6 per condition), MAO-A inhibition kinetics using purified recombinant enzyme preparations, and LC-MS/MS phytochemical characterization of stem extracts, collectively providing mechanistic but not clinically actionable efficacy data. Observational and open-label studies on full ayahuasca ceremonies (which combine B. caapi with Psychotria viridis or other DMT-containing plants) suggest antidepressant and anxiolytic effects in humans, but these cannot be attributed specifically to B. caapi alkaloids versus N,N-dimethyltryptamine (DMT) or synergistic interactions. The overall evidence base warrants classification as preliminary-to-preclinical, with a recognized need for phase I/II dose-escalation trials using standardized B. caapi-only extracts before therapeutic claims can be substantiated.
Preparation & Dosage
Traditional preparation
**Traditional Ayahuasca Decoction**
100–150 g of fresh vine per person) are macerated and slow-boiled for several hours, often combined with Psychotria viridis leaves; the resulting decoction is administered in ceremonial contexts under shamanic supervision
Stems of B. caapi (typically .
**Standardized Dried Stem Extract (Research Grade)**
Commercial extracts are standardized to harmine 1.36% and harmaline 0.24% by mass; in vitro testing employed concentrations of 0.5–64 µg/mL, with anti-inflammatory effects observed at 2–8 µg/mL and cytotoxicity emerging above 4–64 µg/mL depending on cell type.
**Isolated β-Carboline Alkaloids (Preclinical)**
Harmine and harmaline have been tested in cell systems at 2.5–302 µM; no human-validated safe supplemental dose range has been established for isolated alkaloids from B. caapi.
**Capsule/Tincture Forms**
Some commercial preparations offer encapsulated vine powder or hydroalcoholic tinctures standardized to β-carboline content, but no clinically validated dosage protocol exists; use in these formats occurs outside regulatory frameworks in most jurisdictions.
**Timing and Context**
Traditional use is episodic (ceremonial, not daily); the MAOI pharmacology of harmine and harmaline necessitates a minimum 14-hour washout before or after consuming serotonergic agents or tyramine-rich foods to mitigate hypertensive or serotonergic crisis risk.
**Important Note**
No evidence-based standardized supplemental dosing regimen for B. caapi as a standalone health supplement has been established in peer-reviewed clinical literature; all dosing frameworks referenced above derive from traditional practice or preclinical research contexts.
Nutritional Profile
Banisteriopsis caapi stem is not consumed as a dietary food source and does not contribute meaningfully to macronutrient intake; its nutritional relevance lies entirely in its phytochemical constituents. Key bioactive phytochemicals in standardized dried stem extracts include harmine (1.26–3.71% w/w), tetrahydroharmine (0.29–3.48% w/w), harmaline (0.12–0.59% w/w), epicatechin (0.6–5.4% w/w), and procyanidin B2 (0.9–7.2% w/w). Minor LC-MS/MS-identified fractions include compounds at m/z 174.0918, 233.1289, 353.1722, 304.3001, 188.1081, and 205.0785, representing partially characterized alkaloid and polyphenol metabolites. Bioavailability of β-carboline alkaloids from aqueous decoctions is influenced by gastrointestinal pH, co-ingested plant matrices, and first-pass hepatic metabolism; harmine undergoes rapid O-demethylation to harmol, which is then conjugated for urinary excretion, with peak plasma levels in human pharmacokinetic models occurring within 1–2 hours of oral administration in ayahuasca contexts.
How It Works
Mechanism of Action
The primary mechanism of Banisteriopsis caapi centers on reversible, competitive inhibition of monoamine oxidase A (MAO-A) by its β-carboline alkaloids: harmine binds MAO-A with IC₅₀ of 2.0 nM, harmaline at 2.5 nM, and tetrahydroharmine (THH) at 74 nM, collectively reducing oxidative deamination of serotonin, dopamine, and norepinephrine and elevating synaptic monoamine concentrations. At the molecular level, harmaline and the alkaloid-enriched fraction F5 suppress NF-κB-associated pro-inflammatory signaling in BV-2 microglial cells, reducing transcription and secretion of IL-2, IL-6, IL-17, and TNF at concentrations ≥2.5 µM, while THH achieves similar cytokine suppression at ≥9.3 µM. At cytotoxic concentrations (harmine ≥75.5 µM), the alkaloids induce reactive oxygen species (ROS) generation, mitochondrial stress, and necrotic cell death in BV-2 cells after 24 hours, indicating a concentration-dependent biphasic profile—anti-inflammatory at low doses, cytotoxic at high doses. Flavonoid constituents epicatechin and procyanidin B2 contribute secondary antioxidant mechanisms through direct radical scavenging and chelation of transition metals, partially counterbalancing ROS produced at higher alkaloid exposures.
Clinical Evidence
No completed randomized controlled trials or phase I–III clinical studies specifically examining Banisteriopsis caapi as a standalone intervention have been published to date. In vitro studies using BV-2 microglial cell models (n=5–6 per experimental condition) demonstrated statistically significant cytokine suppression (IL-2, IL-6, IL-17, TNF) with harmaline and fraction F5 at ≥2.5 µM, and MAO-A inhibition assays confirmed harmine IC₅₀ of 2.0 nM under standardized enzyme conditions, but these outcomes do not translate directly to clinical effect sizes in humans. Research on composite ayahuasca preparations (containing both B. caapi and DMT-source plants) has shown reductions in depression rating scale scores in open-label and observational designs, but these findings cannot be disaggregated to isolate the vine's contribution. Confidence in therapeutic outcomes specific to B. caapi remains low; the existing preclinical data supports biological plausibility for CNS anti-inflammatory and monoaminergic effects but requires prospective human trials with standardized extracts and appropriate controls to establish clinical relevance.
Safety & Interactions
At concentrations ≥75.5 µM, harmine decreases BV-2 microglial cell viability within 2 hours and induces necrosis and reactive oxygen species (ROS) accumulation after 24 hours; fraction F4 from LC-MS/MS fractionation also demonstrates cytotoxicity at 24-hour exposures in vitro, suggesting a narrow therapeutic window relative to toxic concentrations that has not been characterized in human pharmacokinetic studies. The MAO-A inhibitory activity of harmine and harmaline at nanomolar potency creates clinically significant drug interaction risks: concurrent use with serotonergic agents (SSRIs, SNRIs, tramadol, triptans), other MAOIs, meperidine, or stimulants may precipitate serotonin syndrome, while consumption of tyramine-rich foods (aged cheeses, fermented meats, red wine) risks hypertensive crisis through the 'cheese effect.' Contraindications include personal or family history of schizophrenia or psychotic disorders, cardiovascular disease with hypertension, current use of any serotonergic or sympathomimetic medications, hepatic insufficiency (due to hepatic β-carboline metabolism), and pregnancy or lactation (no safety data; psychoactive alkaloids are presumed to cross the placenta and enter breast milk). No maximum safe dose has been established by any regulatory authority for B. caapi as a standalone supplement; its scheduling status varies by jurisdiction, and in several countries (including the Netherlands and certain US contexts) β-carboline alkaloids are unscheduled while the full ayahuasca preparation occupies a legal gray area.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Ayahuasca vineMareación vineCaapiAyahuasca Vine (Banisteriopsis caapi)Banisteriopsis caapiNatemaBejuco de oroYagé
Frequently Asked Questions
What are the main active compounds in Banisteriopsis caapi?
The primary bioactive compounds are β-carboline alkaloids: harmine (1.26–3.71% w/w), harmaline (0.12–0.59% w/w), and tetrahydroharmine or THH (0.29–3.48% w/w) in standardized dried stem extracts. These are complemented by flavonoids epicatechin (0.6–5.4%) and procyanidin B2 (0.9–7.2%), which contribute antioxidant activity. Together these constituents drive the vine's MAO-inhibitory and anti-inflammatory pharmacological profile.
How does Banisteriopsis caapi work as an MAOI?
Harmine and harmaline in B. caapi reversibly and competitively inhibit monoamine oxidase A (MAO-A) with IC₅₀ values of 2.0 nM and 2.5 nM respectively, making them among the most potent natural MAO-A inhibitors identified. This inhibition reduces the enzymatic breakdown of serotonin, dopamine, and norepinephrine, elevating monoamine levels in the synaptic cleft. In the context of ayahuasca, this MAOI action is pharmacologically critical because it prevents intestinal and hepatic degradation of co-ingested DMT, enabling its oral bioavailability.
Is Banisteriopsis caapi safe to take as a supplement?
No standardized safe supplemental dose of B. caapi as a standalone ingredient has been established in human clinical trials. The β-carboline alkaloids carry significant drug interaction risks due to MAO-A inhibition, particularly with serotonergic medications (SSRIs, SNRIs, triptans) where serotonin syndrome is a documented risk, and with tyramine-containing foods where hypertensive crisis is possible. It is contraindicated in individuals with psychotic disorders, cardiovascular disease, hepatic impairment, and during pregnancy or lactation; any use should involve medical supervision.
What is the difference between Banisteriopsis caapi and ayahuasca?
Banisteriopsis caapi is one plant—a woody Amazonian liana—whose stems provide the MAOI-active β-carboline alkaloids (harmine, harmaline, THH) that form the pharmacological backbone of the ayahuasca brew. Ayahuasca is a composite preparation that typically combines B. caapi with a DMT-containing plant such as Psychotria viridis; the vine alone does not produce the full visionary psychedelic experience associated with ayahuasca ceremonies. The vine's MAO inhibition is essential to the combined preparation because it prevents oral degradation of DMT, but the two ingredients serve distinct and complementary roles.
Does Banisteriopsis caapi have anti-inflammatory or neuroprotective effects?
Preclinical in vitro evidence in BV-2 murine microglial cells shows that harmaline and the alkaloid-enriched fraction F5 suppress pro-inflammatory cytokines IL-2, IL-6, IL-17, and TNF at concentrations ≥2.5 µM, with F5 reducing cytokines to undetectable levels at higher doses, suggesting meaningful anti-inflammatory activity at the cellular level. THH achieves similar cytokine suppression at ≥9.3 µM, and the flavonoid constituents provide complementary antioxidant protection. However, these effects have only been demonstrated in cell culture models; no human clinical trials have confirmed neuroprotective or anti-inflammatory outcomes from isolated B. caapi extracts.
Does Banisteriopsis caapi interact with antidepressants or SSRIs?
Banisteriopsis caapi contains potent MAO-A inhibitors (harmine and harmaline) that can significantly increase serotonin levels and potentially cause serotonin syndrome when combined with SSRIs, SNRIs, or other serotonergic medications. Co-administration with antidepressants is contraindicated without medical supervision due to the risk of dangerous monoamine accumulation. Any use of Banisteriopsis caapi alongside psychiatric medications requires explicit approval from a healthcare provider experienced with MAOI interactions.
Who should avoid Banisteriopsis caapi supplementation?
Individuals taking SSRIs, MAO inhibitors, stimulant medications, or those with uncontrolled hypertension, heart disease, or a history of psychosis should avoid Banisteriopsis caapi due to serious interaction and safety risks. Pregnant and nursing women should not use this ingredient, as safety data is insufficient and monoamine modulation may affect fetal development. People with bipolar disorder or those on multiple psychoactive substances should consult a healthcare provider before considering use.
What does the clinical research evidence show about Banisteriopsis caapi's mood and cognitive effects?
In vitro studies demonstrate potent MAO-A inhibition with IC₅₀ values as low as 0.024–0.047 µg/mL, supporting theoretical mechanisms for monoamine elevation relevant to mood regulation. However, human clinical trials specifically examining isolated Banisteriopsis caapi supplementation (outside of ayahuasca ceremony contexts) are limited, making it difficult to quantify efficacy and optimal dosing for mood or cognitive benefits. Most evidence comes from traditional use reports and preliminary pharmacological studies rather than randomized controlled trials in supplement contexts.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w banisteriopsis-caapi-ayahuasca-vine curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
